New drug tested as last hope for aggressive brain cancer
NCT ID NCT03149575
Summary
This study tested an experimental drug called VAL-083 for adults with glioblastoma, a fast-growing brain cancer that had returned after standard treatments failed. It compared VAL-083 against a doctor's choice of other approved chemotherapy drugs to see which helped patients live longer. The trial was designed to enroll up to 180 people but was stopped early after only 2 participants joined.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Neuroscience Institute - Brain Tumor Center of NJ
Summit, New Jersey, 07901, United States
-
Dent Neurosciences Research Center
Amherst, New York, 14226, United States
-
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
University of California, San Francisco - Division of Neuro-Oncology
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.